Citizens cuts Rocket Lab stock price target on Neutron delay to 2027

Rocket Lab delayed Neutron’s inaugural flight from the fourth quarter of 2026 to 2027 after air bubbles were found in part of the first-stage lower carbon-composite tank, which failed to meet safety margins. The company said it fixed the manufacturing process, validated it on a second tank section, and is rebuilding the affected portion. Citizens cut its price target to $90 from $130 but maintained Market Outperform; KeyBanc also lowered its target, while Cantor Fitzgerald and Stifel reiterated positive ratings. Rocket Lab was down approximately 21% year-to-date, versus 7.6% for the S&P Aerospace & Defense ETF and a 12% gain for the Russell 3000.

Analysis

The key risk is not simply a later first flight: Neutron’s schedule now depends on whether Rocket Lab can reproduce the revised composite-tank process across the full structure and complete qualification without further rework. A successful coupon or section validation is encouraging but does not establish full-stage reliability. Until that evidence arrives, investors should discount the timing and execution value embedded in Neutron rather than treat analyst price targets as confirmation; those targets are opinions, not new technical validation.

Near term, another qualification issue could pressure RKLB through both a longer wait for Neutron-related economics and a higher perceived execution-risk premium. Over 1–3 months, watch for full-tank test results, manufacturing cadence, and any change in company guidance. Over 6–18 months, a clean qualification path would restore credibility, while repeated rework could shift customer opportunities toward other launch providers, including SpaceX and Firefly Aerospace; that substitution is conditional, not an automatic transfer of contracts. Rocket Lab’s established activities may provide some diversification, but the article does not quantify how much they offset Neutron risk.

Contrarian read: the safety-margin decision may protect long-run program value, so treating the delay as proof of technical failure would be premature. Conversely, supportive analyst ratings may underweight the possibility that a component-level fix fails to scale. The relative underperformance cited in the article suggests some repricing has occurred, but does not establish that schedule risk is fully reflected.

Key Decisions for Investors

• Keep a tactical underweight in RKLB versus a diversified aerospace-and-defense ETF until Rocket Lab demonstrates full-tank qualification and provides a credible, milestone-based schedule. Avoid adding solely because analyst ratings remain positive.
• If holding RKLB, consider defined-risk downside protection rather than an outright short; option pricing and liquidity should be checked first. Reassess after full-stage test results or a material guidance update.
• Watch for evidence of rework beyond the affected tank section, missed qualification milestones, or customer schedule changes. Any of these would strengthen the downside thesis; successful full-tank testing and sustained schedule confidence would falsify it and support covering hedges.
• Do not assume competing launch providers gain revenue from this delay without evidence of customer reassignment or capacity constraints; monitor contract announcements and launch schedules for confirmation.